Results from a retrospective population-based cohort study showed that patients diagnosed with myelofibrosis have an increased risk of venous, but not arterial thromboembolism. These findings were published in the Journal of Thrombosis and Haemostasis.

Of the 3 Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs), polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF), the latter disease, characterized by replacement of normal bone marrow with fibrosis scar tissue, is least common and associated with the worst prognosis. Furthermore, both PV and ET can progress to secondary myelofibrosis.

Although previous studies have established the increased risk of thromboembolism in patients with PV and ET, less is known about the incidence of arterial and venous thromboembolic events in the setting of either PMF or myelofibrosis secondary to either PV or ET.

Related Articles

This case-control study included 642 patients with myelofibrosis along with 2568 control patients without the disease who were matched according to patient- and disease-specific factors, such as age, sex, and index date (the date on which myelofibrosis was diagnosed). Patient information was obtained from an administrative database that included the electronic medical records of a cohort of more than 1 million adults residing in Israel.

The mean age at which myelofibrosis was diagnosed was 66.5 years. Of the more than 40% of patients with myelofibrosis who underwent genotyping, 64.0% were classified as having disease characterized by JAKV617F. Regarding comorbidities present at the index date, those with myelofibrosis were significantly more likely to have a previous diagnosis of diabetes (P =.042), congestive heart failure (P <.001), cirrhosis (P <.001), chronic obstructive pulmonary disease, (P =.014), chronic renal failure (P <.001), previous thromboembolism (P <.001), previous lymphoma (P =.014), PV (P <.001), and ET (P <.001).

This article originally appeared on Oncology Nurse Advisor